Loxo Oncology, Inc. Form 8-K May 12, 2016

# UNITED STATES SECURITIES AND EXCHANGE COMMISSION

**WASHINGTON, DC 20549** 

## FORM 8-K

# CURRENT REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report: May 11, 2016

(Date of earliest event reported)

# LOXO ONCOLOGY, INC.

(Exact Name of Registrant as Specified in Its Charter)

#### Delaware

(State or Other Jurisdiction of Incorporation)

001-36562 (Commission File Number) 46-2996673 (IRS Employer Identification No.)

281 Tresser Blvd., 9th Floor Stamford, CT (Address of Principal Executive Offices)


**06901** (Zip Code)

#### (203) 653-3880

(Registrant s Telephone Number, Including Area Code)

#### Not Applicable

(Former name or former address, if changed since last report.)



- o Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
- o Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
- o Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
- o Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

#### Item 1.01. Entry into a Material Definitive Agreement.

On May 11, 2016, Loxo Oncology, Inc. ( Loxo Oncology ) entered into an underwriting agreement (the Underwriting Agreement ) with Citigroup Global Markets Inc. and Cowen and Company, LLC, as representatives of several underwriters named on Schedule II thereto (the Underwriters), pursuant to which Loxo Oncology agreed to issue and sell an aggregate of 1,675,000 shares of its common stock (the Shares) to the Underwriters (the Offering). The Shares will be sold at a per share public offering price of \$21.50. Pursuant to the Underwriting Agreement, Loxo Oncology also granted the Underwriters a 30-day option to purchase up to an additional 251,250 shares of its common stock. The Underwriting Agreement contains customary representations and warranties, conditions to closing, market standoff provisions, termination provisions and indemnification obligations, including for liabilities under the Securities Act of 1933, as amended. The Offering will be made pursuant to a shelf registration statement on Form S-3 (File No. 333-206052) that was filed by Loxo Oncology with the Securities and Exchange Commission (SEC) on August 3, 2015 and declared effective by the SEC on August 11, 2015.

Loxo Oncology estimates that net proceeds from the Offering will be approximately \$33.5 million, after deducting underwriting discounts and commissions and estimated Offering expenses, and assuming no exercise of the Underwriters option to purchase additional shares. Loxo Oncology intends to use the net proceeds from the Offering for general corporate purposes, which may include funding research and development, increasing its working capital, acquisitions or investments in businesses, products or technologies that are complementary to its own and capital expenditures. Loxo Oncology expects the Offering to close on May 17, 2016, subject to customary closing conditions. The shares will be listed on the NASDAQ Global Market.

The foregoing description of the Underwriting Agreement does not purport to be complete and is qualified in its entirety by reference to the full text of the Underwriting Agreement. A copy of the Underwriting Agreement is filed with this Current Report on Form 8-K as Exhibit 1.1 and is incorporated herein by reference.

A copy of the opinion of Fenwick & West LLP, relating to the validity of the Shares in connection with the Offering, is filed with this Current Report on Form 8-K report as Exhibit 5.1.

#### Item 8.01. Other Events.

On May 11, 2016, Loxo Oncology issued a press release, announcing the pricing of the Offering. A copy of the press release is filed with this Current Report on Form 8-K as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.

#### Exhibit Number

- 1.1 Underwriting Agreement dated May 11, 2016
- 5.1 Opinion of Fenwick & West LLP
- 23.1 Consent of Fenwick & West LLP (contained in Exhibit 5.1)
- 99.1 Press release dated May 11, 2016

#### Forward-Looking Statements

This Current Report on Form 8-K contains forward-looking statements within the meaning of the U.S. Private Securities Litigation Reform Act of 1995 and other federal securities laws. Any statements contained herein that do not describe historical facts, including, but not limited to, statements regarding the anticipated use of proceeds of the Offering and the timing of completion of the Offering, are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those discussed in such forward-looking statements. Such risks and uncertainties include, among others, the risks identified in Loxo Oncology s filings with the SEC, including its Quarterly Report on Form 10-Q for the quarter ended March 31, 2016, filed with the SEC on May 4, 2016, the prospectus supplement related to the Offering, and subsequent filings with the SEC. Any of these risks and uncertainties could materially and adversely affect Loxo Oncology s results of operations, which would, in turn, have a significant and adverse impact on Loxo Oncology stock price. Loxo Oncology cautions you not to place undue reliance on any forward-looking statements, which speak only as of the date they are made. Loxo Oncology undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date they were made or to reflect the occurrence of unanticipated events.

#### **SIGNATURES**

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Loxo Oncology, Inc.

Date: May 11, 2016 By: /s/ Jennifer Burstein

Name: Jennifer Burstein

Title: Vice President of Finance and

principal financial officer

3

### INDEX TO EXHIBITS

Exhibit Number	Description of Exhibit
1.1	Underwriting Agreement dated May 11, 2016
5.1	Opinion of Fenwick & West LLP
23.1	Consent of Fenwick & West LLP (contained in Exhibit 5.1)
99.1	Press release dated May 11, 2016
	4